Front PageNational News Pakistan
Send News Request
National•International Bureau•19 Nov 2026, 05:43 PM PKT•2 min read•1,781 Reads

New Blood Cancer Vaccine Reduces Death Risk By 41%

A new vaccine designed to treat an aggressive form of blood cancer has shown promising results in a major clinical… Read More The post New Blood Cancer Vaccine Reduces Death Risk By 41% appeared first on ProPakistani. National News Pakistan correspondents report that administrative desks and on-ground observers are closely monitoring developments across Pakistan.

60-Second Editorial Quick Summaryخلاصہ

Verified facts & intelligence briefed by National News Press Bureau.

A new vaccine designed to treat an aggressive form of blood cancer has shown promising results in a major clinical trial, reducing the risk of death among certain leukemia patients by 41%.

According to field observations and verified reporting compiled by the International bureau desk: The vaccine, known as galinpepimut-S (GPS), was developed at Memorial Sloan Kettering Cancer Center and tested by Sellas Life Sciences in a Phase 3 clinical trial involving 126 patients with acute myeloid leukemia (AML).

According to results announced, patients who received the vaccine survived for a median of 24 months, compared with 14.7 months for those receiving other available treatments.

NNP Central Editorial Research Desk
#Pakistan National Bureau#National Desk
WhatsApp𝕏 PostFacebook
New Blood Cancer Vaccine Reduces Death Risk By 41%
Photo: National News Pakistan Bureau

INTERNATIONAL BUREAU —A new vaccine designed to treat an aggressive form of blood cancer has shown promising results in a major clinical trial, reducing the risk of death among certain leukemia patients by 41%.

According to field observations and verified reporting compiled by the International bureau desk: The vaccine, known as galinpepimut-S (GPS), was developed at Memorial Sloan Kettering Cancer Center and tested by Sellas Life Sciences in a Phase 3 clinical trial involving 126 patients with acute myeloid leukemia (AML). According to results announced, patients who received the vaccine survived for a median of 24 months, compared with 14.7 months for those receiving other available treatments. The clinical trial focused on patients whose leukemia had returned after previous treatment but who had achieved another remission and were ineligible for bone marrow transplants.

Civic administrative directorates and regional executive authorities in International have initiated inter-departmental coordination to uphold regulatory compliance, civic order, and public welfare standards regarding this situation.

Civil society representatives and local community members in International have urged administrative authorities to ensure transparent communication and rapid service delivery to address citizen requirements effectively.

The Central Editorial Desk of National News Press continues to monitor on-ground developments in real time, with verified updates and formal departmental communiqués to be published as official notifications are finalized.

Key Takeaways & Executive Analysis

  • A new vaccine designed to treat an aggressive form of blood cancer has shown promising results in a major clinical trial, reducing the risk of death among certain leukemia patients by 41%.
  • According to field observations and verified reporting compiled by the International bureau desk: The vaccine, known as galinpepimut-S (GPS), was developed at Memorial Sloan Kettering Cancer Center and tested by Sellas Life Sciences in a Phase 3 clinical trial involving 126 patients with acute myeloid leukemia (AML).
  • According to results announced, patients who received the vaccine survived for a median of 24 months, compared with 14.7 months for those receiving other available treatments.
Verified National Coverage: Published by National News Press (International Bureau). Fact-checked and verified.
Verified Editorial Desk
WhatsApp𝕏 PostFacebook

Audience Reviews & Discussion

Share your perspective, rate coverage accuracy, and engage with verified readers across Pakistan.

Rate This Story

Join the Discussion

Civic discussion moderated by NNP Editorial Desk

Community Comments (0)